Print Page      Close Window

Investor Overview

Corporate Profile

Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer from within. Tocagen is currently studying its lead product candidate, Toca 511 & Toca FC, in a Phase 2/3 clinical trial for the treatment of patients with recurrent high grade glioma (HGG), a type of brain cancer with limited treatment options. Toca 511 & Toca FC has been granted Breakthrough Therapy Designation for the treatment of patients with recurrent HGG by the FDA.
NASDAQ GS TOCA (Common Stock)
$13.41 + 0.06
Stock chart for: TOCA.O.  Currently trading at $13.41 with a 52 week high of $14.72 and a 52 week low of $10.25.
04/27/17 10:32 a.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent News

View All  

Tocagen Announces Closing of Initial Public Offering and Exercise of the Underwriters' Option


Read More

Tocagen Announces Pricing of Initial Public Offering


Read More

Tocagen to Present Anti-Tumor Immune Response Data at 2017 Keystone Symposia


Read More

Upcoming Events

View All  
There are currently no events scheduled.